Skip to content

Combating Opioid Dependence

Combating Opioid Dependence

The opioid epidemic is a hot topic across the United States, along with the alternatives that could alleviate the tragic consequences the epidemic brings. Opioids, also known as narcotics, are strong prescription pain relievers such as oxycodone, hydrocodone and fentanyl. Although illegal, heroin is also considered to be an opioid. Most patients are introduced to these strong narcotics after a major injury or surgery and should only use them on a short-term basis. Unfortunately, this short-term timeline is not always followed, and the patient can become dependent on the pain killers for everyday life.

Understanding Opioid Dependence

Every day, more than 130 people in the United States die from an opioid overdose – including prescription pain relievers, heroin and synthetics. See below for additional facts we’ve uncovered regarding the opioid crisis:

  • Roughly 21-29% of patients prescribed opioids for chronic pain misuse them
  • Between 8-12% develop an opioid use disorder
  • An estimated 4-6% who misuse prescription opioids transition to heroin
  • About 80% of people who use heroin first misused prescription opioids

Ultimately, the opioid epidemic has become a severe national crisis that affects public health as well as social and economic welfare. Not only does the devastating issue carry consequences like an increase in opioid misuse and related overdoses, it’s also a catalyst for neonatal abstinence syndrome due to opioid use during pregnancy. As more opioid users turn to something stronger, like heroin, an increase in injection drug use follows, contributing to the spread of infectious diseases such as HIV and hepatitis C.

A Better Option

Both prescription opioids and cannabis have the same primary use: analgesia – the inability to feel pain. Currently, up to 90% of patients in state-level medical cannabis registries list chronic pain as their qualifying condition. According to a review conducted by the National Academies of Science and Medicine, when given access to cannabis, patients currently using opioids for chronic pain decreased their use by 40-60% and reported that they prefer cannabis rather than opioids. Patients also reported fewer side effects with cannabis and a better quality of life compared to opioids. 

Although there is minimal clinical literature that supports the use of cannabis as a treatment for acute pain, there is a long-standing body of pre-clinical evidence that demonstrates the effectiveness of cannabinoids in providing a pain-free life in drug-naïve animals.

“The mechanisms of cannabinoid antinociception are remarkably similar to those of opioid analgesics. Both the CB1 and MOR are G-protein coupled receptors, and agonist-initiated disinhibition of GABA release in the descending pain pathway is just one example of overlapping antinociceptive mechanisms between these drugs.” -NCBI.gov

The evidence we do have that supports the role of cannabis in acute, nonsevere pain management could lead to a substantial reduction in opioid prescription use. This increase in medical marijuana use for treating acute pain could eliminate patients being exposed to the risks of opioid dose escalation and physical dependence. We still have a long way to go, but the potential impact of this therapy definitely warrants further exploration of the efficacy of cannabis for pain relief and eliminating opioid dependence.

Interested in learning more about medical cannabis efficacies for opioid dependence or other qualifying conditions? Join Arfinn Med for FREE today to access HIPAA compliant peer-to-peer data on medical marijuana treatment efficacies, discuss treatment plans with other licensed physicians and stay up-to-date on all of the latest industry findings.

Sources: https://medlineplus.gov/healthtopics/opioidabuseandaddiction_b.html?utm_expid=.YDctbaKlRwemM6rjn-4YCA.2&utm_referrer=https%3A%2F%2Fwww.google.com%2F

https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135562/

Stories you may be interested in

Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness

When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More

Americans Are Googling CBD More Than Acupuncture, Meditation And Exercise, Study Finds

People are increasingly more interested in CBD—or cannabidiol—than other health trends such as acupuncture, apple cider vinegar, exercise and veganism, according to a new review. In fact, the non-intoxicating cannabis compound has risen in popularity so much that people Google it nearly as much as they do for yoga and e-cigarettes. In a paper published…
Read More

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More

Leave a Comment

You must be logged in to post a comment.